The Role of rs10811661 Polymorphism in the CDKN2A/B Gene: A Narrative Review of Prognostic Biomarker for Colon and Gastric Cancers

Abstract

Context: The rs10811661 polymorphism in the CDKN2A/B gene has emerged as a potential prognostic biomarker for colon and gastric cancers, both of which significantly contribute to global cancer mortality. Identifying genetic factors that influence cancer progression is crucial for enhancing early detection and patient outcomes. This narrative review explores the molecular mechanisms by which rs10811661 impacts tumor development, particularly its role in cell cycle regulation, insulin signaling, and ANRIL, a long non-coding RNA involved in gene expression modulation. Evidence Acquisition: The present research indicates that patients with the TT genotype of rs10811661 are at a higher risk of developing more aggressive and invasive forms of colon and gastric cancer. In colon cancer, the TT genotype is linked to advanced tumor stages and increased invasiveness, with notable sex-specific differences, particularly among female patients. Results: In gastric cancer, this polymorphism is associated with earlier onset and rapid progression, especially in younger patients carrying the TT genotype. The rs10811661 polymorphism shows promise as a diagnostic and prognostic marker, allowing clinicians to stratify patients based on genetic risk and personalize treatment approaches. Conclusions: Integrating genetic testing for rs10811661 into routine clinical assessments could enhance early detection and optimize cancer management strategies. Further research is needed to explore its broader implications across other cancers and its interactions with environmental factors, including lifestyle and diet.